Bifogade filer
20240529 Saniona Q1 2024 (UK)
Kurs
+0,99%
Likviditet
0,68 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2026-02-26 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-27 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-28 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | N/A | Årsstämma |
| 2025-05-28 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-27 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-28 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2024-05-25 | - | Årsstämma |
| 2024-02-29 | - | Bokslutskommuniké 2023 |
| 2024-01-16 | - | Extra Bolagsstämma 2024 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | Årsstämma |
| 2023-05-25 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-24 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-08-18 | - | Extra Bolagsstämma 2022 |
| 2022-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-05-25 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-09-16 | - | Extra Bolagsstämma 2021 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-17 | - | Bokslutskommuniké 2020 |
| 2020-11-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-23 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-28 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2020-05-06 | - | Årsstämma |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-07 | - | Extra Bolagsstämma 2019 |
| 2020-02-07 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2019-05-29 | - | Årsstämma |
| 2019-05-29 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-21 | - | Bokslutskommuniké 2018 |
| 2018-11-14 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-21 | - | Bokslutskommuniké 2017 |
| 2018-01-19 | - | Extra Bolagsstämma 2018 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2017-05-23 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-21 | - | Bokslutskommuniké 2016 |
| 2016-10-13 | - | Extra Bolagsstämma 2016 |
| 2016-05-11 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2016-05-10 | - | Årsstämma |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-11-20 | - | Kvartalsrapport 2015-Q3 |
| 2015-09-04 | - | Extra Bolagsstämma 2015 |
| 2015-08-31 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-21 | - | X-dag ordinarie utdelning SANION 0.00 SEK |
| 2015-05-20 | - | Årsstämma |
| 2015-05-20 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-20 | - | Bokslutskommuniké 2014 |
| 2014-11-21 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-22 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
| Q1 2024 (Q1 2023) |
| Revenue was SEK 6.0 M (2.2) |
| Operating profit/loss was SEK -13.7 M (-21.1) |
| Net profit/loss was SEK -9.2 M (-21.7) |
| Cash and cash equivalent SEK 71.4 M (87.8) |
| Basic earnings/loss per share was SEK -0.08 (-0.35) |
| Diluted earnings/loss per share were SEK -0.08 (-0.35) |
Business highlights in Q1 2024
- On January 2, Saniona announced selection of SAN2465 as a preclinical candidate for major depressive disorder.
- On January 10, the board of directors resolved on an issue of units consisting of shares and warrants with preferential rights for the existing shareholders, which was approved at the extraordinary general meeting on January 16, 2024.
- On February 7, Saniona announced outcome in the rights issue of a proceed of approximately SEK 88.9 million before issue costs. On February 15, Saniona also announced a directed issue of units to guarantors in the rights issue as well as convertibles of SEK 10 million to Formue Nord.
Significant events after the reporting period
- On May 7, Saniona reported progress on pipeline and other activities.
Comments from the CEO
“After strengthening our financial position through a rights issue, we are now focusing on advancing our epilepsy assets to provide clinical proof of concept for SAN711 and preparing SAN2355 for Phase 1, while we are exploring new partnership opportunities. With a strong efficacy and safety profile, and a potential approval in Mexico this year, tesofensine could address a significant medical need and generate new revenue streams for Saniona.”
For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline features SAN711, a Phase 2-ready candidate drug targeting absence seizures, SAN2219 for acute repetitive seizures, and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine, Saniona’s most advanced candidate, is progressing towards regulatory approval for obesity in Mexico through a partnership with Medix. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona has esteemed partners, including Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market.
For more information, please visit www.saniona.com.
Attachments
20240529 Saniona Q1 2024 (UK)